Praxis Precision price target raised to $353 from $251 at TD Cowen

TD Cowen analyst Ritu Baral raised the firm’s price target on Praxis Precision (PRAX) to $353 from $251 and keeps a Buy rating on the shares. The firm noted they presented updated Ph2 RADIANT and key interim EMBOLD data. In FOS, vormatrigine led to a roughly 100% median seizure reduction by wee 8, with seizure frequency declining over time. Also, a roughly 80% median seizure reduction was seen in generalized epilepsy.